DUBLIN-- ( BUSINESS WIRE )-- ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the third quarter ended ...

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Icon (ICLR – Research Report), with a price ...

Robert W. Baird analyst Eric Coldwell downgraded the rating on Icon (ICLR – Research Report) to a Hold today, setting a price target of ...

Leal Therapeutics raised $45 million for drug development, including advancing a promising therapy into clinical trials for ...

It seems reports of the All Blacks’ demise have been greatly exaggerated. A middling Rugby Championship campaign had made for ...

Think twice before buying your favorite influencer's supplement du jour. Here's how to choose the right longevity products, and when to hold back.

Jazmin Evans was diagnosed with kidney disease at the age of 17 in 2012. She received a kidney transplant in July 2023, after ...

A first healthy adults group has been dosed in an early clinical trial of an oral and myelin-protective treatment for all ...

Ricky Kej, a three-time Grammy winner, earned a nomination in the Best New Age, Ambient, or Chant Album category for his ...

Hope Biosciences' stem cell therapy led to improved scores on a quality-of-life test for MS patients in a small clinical trial.

Fintel reports that on October 14, 2024, Redburn Atlantic initiated coverage of ICON Public Limited (NasdaqGS:ICLR) with a Neutral recommendation. Analyst Price Forecast Suggests 26.49% Upside As of ...

Long-term treatment with the cell therapy NurOwn was found to significantly extend survival for ALS patients compared with ...